Search for a trial

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

This study has been transitioned to CTIS with ID 2023-503291-24-00 check the CTIS register for the current data. Main objective:Dose Escalation Part:• To assess the safety and tolerability of DF1001 monotherapy, and to determine the Maximum…